FDA Approves First Gene Therapy for Genetic Deafness
FDA Approves First Gene Therapy for Genetic Deafness
The Spin
The FDA's approval of Otarmeni marks a genuine turning point in medicine — 80% of trial participants hit the primary hearing endpoint, and 42% achieved normal hearing, including whispers. This one-time gene therapy restores what was once considered permanent deafness, and Regeneron is offering it free to eligible U.S. patients. Science delivered a real cure here, and that matters.
Cures have existed while billions in public and private funding flowed into systems built to manage diseases, not eliminate them. The FDA greenlit Otarmeni in 61 days when the incentives finally aligned, proving the bottleneck was never scientific — it was structural. National priority vouchers and market alignment can unlock breakthroughs that bureaucracy quietly buries.
Metaculus Prediction
There's a 26.7% chance that the U.S., U.K., or EU will approve a gene-editing therapy for a new condition in 2026, according to the Metaculus prediction community.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.4.1